Strategy. From people who have held the role.
12+
Decades
Preclinical to LCM
Operator Led
The thesis.
Most strategy fails the same way: a confident slide presentation by people who have never had to make it work. An unrealistic peak-sales figure. A pricing strategy no payer would allow. A sales approach no rep would carry. A launch plan that assumes the competitor will stand still. A portfolio call made on the team's gut, not the market's reality. Beacon was built by operators to close that gap — to bring the judgment that only comes from having owned the brand, the launch, and the P&L, and to back it with bottom-up rigor and the voice of the people who decide whether a strategy wins or loses.
Kevin Rooney, Founder & President
Kevin Rooney founded Beacon Consulting Group after a 25-year career that took him from sales representative to the C-suite, and nearly every role in between. He has “carried the bag” as a sales representative, run regional and national sales teams, led marketing for $1B+ brands, been responsible for entire businesses, and served in C-level Commercial and Corporate Strategy roles at multiple biotech and specialty pharma companies.
Along the way he launched more than a dozen brands across oncology, ID, rare disease, CV, anesthesia, CNS, and multiple other therapeutic areas — at companies including BMS, MedImmune, Glaxo Wellcome, QOL Medical, and NervGen. He has built commercial organizations from the ground up, rebuilt and scaled teams, owned P&Ls, deployed large sales forces, and led the corporate strategy and partnering decisions that determine what a company is worth.
That range is the point. When a leadership team brings Kevin a question — which asset to prioritize, how to launch it, how to build the organization behind it, what a program is truly worth — he has almost certainly faced the same decision himself, with his own name on the outcome. Beacon exists to put that first hand judgment to work for the companies making biopharma's most consequential decisions.
